Applied Clinical Trials
Patients stand to lose the most when sponsors hold too tightly to drugs doomed to fail. This wastes precious time that patients don’t have and squanders valuable resources.
Stephen Gately, PhD
Advertisement
Articles by Stephen Gately, PhD
Applied Clinical Trials
With more common cancers now increasingly broken down by specific genomic defects, the future of research for any cancer is entirely, and unequivocally, molecular.
Advertisement
Latest Updated Articles
Any Cancer Can Be a 'Rare Cancer'June 1st 2018
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
2
Mixed Outsourcing Models Are Spreading. Is Sponsor Oversight Keeping Up?
3
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
4
Hierarchical Endpoints in Cardiology: How Much Treatment Benefit, and From Where
5